Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Peter M Voorhees
Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials
The Lancet Haematology
Hematology
Related publications
Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease
Immunotherapy
Oncology
Allergy
Immunology
FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease
Clinical Cancer Research
Cancer Research
Oncology
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data
British Journal of Haematology
Hematology
Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan
Modern Rheumatology
Medicine
Rheumatology
SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study
Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Biologic Agents in the Treatment of Multicentric Castleman Disease
Turkish Thoracic Journal
Pulmonary
Respiratory Medicine
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
